The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial is a research paper published in Arthritis & Rheumatology (2021). On theSindex it has a DataRank of 4.8. It has been cited 90 times, with 83 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.677
From this paper's citation signal
Citation Network Contribution
4.2
From 74 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 83 citers.
National Institutes of Health
Grant: 1R21AR065959‐01
NIH HHS
Grant: 1R21AR065959-01
NIAMS NIH HHS
Grant: R01 AR076242
NIAMS NIH HHS
Grant: R21 AR065959
National Institutes of Health
Grant: 5R21AR065959-02
IRF5-TNPO3 locus: Inclusion of TNPO3 as a unique regulator of IRF5 expression an
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Pfizer
Pfizer
FWCI
9.58
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Review of potential medical treatments for middle ear cholesteatoma
Additional file 2 of Review of potential medical treatments for middle ear cholesteatoma
Additional file 3 of Review of potential medical treatments for middle ear cholesteatoma
Additional file 3 of Review of potential medical treatments for middle ear cholesteatoma